Mercer Global Advisors Inc. ADV Sells 1,686 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mercer Global Advisors Inc. ADV decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 50.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,641 shares of the specialty pharmaceutical company’s stock after selling 1,686 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Jazz Pharmaceuticals were worth $202,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $464,000. BTC Capital Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 9.4% in the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company’s stock worth $6,115,000 after purchasing an additional 4,271 shares during the last quarter. Summit Trail Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $539,000. Atria Investments Inc grew its stake in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company’s stock worth $336,000 after purchasing an additional 445 shares during the last quarter. Finally, Pacer Advisors Inc. grew its stake in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $108.98 on Friday. The firm’s 50-day moving average price is $115.73 and its 200-day moving average price is $122.01. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a market capitalization of $6.72 billion, a P/E ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the company posted $2.68 EPS. Jazz Pharmaceuticals’s revenue for the quarter was down .5% on a year-over-year basis. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer now owns 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,236 shares of company stock worth $3,956,190. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on JAZZ. Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. HC Wainwright upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.